Mankind Pharma announced its Q2 FY26 financial results showing a revenue increase of 20.8% year-on-year, reaching INR 3,697 Crore with an EBITDA margin of 25.0%. The results reflect growth driven by chronic treatments despite some disruption from GST and weather-related issues.